PEPTIDE GUIDE

What Is Thymagen (Thymogen)?

Thymagen is an online and research-market name usually applied to the dipeptide L-glutamyl-L-tryptophan, shortened to L-Glu-L-Trp or EW. The same sequence is better documented in scientific literature as Thymogen and, in Western cancer development, IM862 or oglufanide.

The molecule was developed through research on the calf-thymus extract Thymalin and studied as an immune-modulating compound. Russian publications describe immune and perioperative uses. Western trials tested IM862 as an anti-angiogenic cancer treatment, including a 202-person Phase III Kaposi's sarcoma trial that found no benefit over placebo and a shorter time to progression in the treatment group.

Names and chemical forms need careful checking. “Thymagen” does not automatically prove that a product is the same stereochemical form, salt, formulation or pharmaceutical material used in a study.

Research statusMixed human evidence; Russian medicine history but no FDA, MHRA or EMA approval
Compound typeSynthetic L-glutamyl-L-tryptophan dipeptide
Human evidenceSmall immune studies and negative controlled cancer trials
ApprovalNot approved by FDA, MHRA or EMA
Last reviewedOctober 2026
THE SHORT ANSWER

Thymagen generally refers to synthetic L-Glu-L-Trp, a two-amino-acid compound more formally known as Thymogen. It is not the Thymalin extract and is not thymosin alpha-1. Russian studies report immune-marker and perioperative findings, including a double-blind placebo-controlled surgical study whose accessible abstract provides limited numerical detail. Under the name IM862, the same L-Glu-L-Trp sequence entered independent cancer trials. An early 44-person Kaposi's sarcoma study produced an apparent response signal, but a subsequent randomised Phase III trial in 202 people found response rates of 23% with IM862 and 21% with placebo, while median time to progression was shorter with IM862. A placebo-controlled prostate-cancer study also failed to show superiority. The compound has human exposure data, but no established anti-cancer, anti-ageing or general immune benefit and no FDA, MHRA or EMA-approved indication.

Is Thymagen the same as Thymogen?

In current peptide catalogues, Thymagen usually identifies the EW dipeptide associated with Thymogen. The peer-reviewed literature overwhelmingly uses Thymogen, IM862 or oglufanide rather than Thymagen.

The shared sequence is L-glutamyl-L-tryptophan. Glutamic acid and tryptophan are joined by a peptide bond, with both amino acids in the L configuration normally used in human proteins.

The name alone is not enough to establish equivalence. A study may use the free acid, an amide, a particular salt or a specific formulation. The bond can also involve different parts of glutamic acid. Analytical identity and stereochemistry must match before evidence can be transferred.

This guide uses Thymagen in the searchable title but Thymogen when discussing the documented medicine and Russian research, and IM862 when discussing the cancer-development formulation.

What is a dipeptide?

A dipeptide contains two amino-acid residues connected by one peptide bond. Thymogen contains glutamic acid followed by tryptophan:

`L-Glu-L-Trp`

Short length makes chemical synthesis and identity testing simpler than for a long peptide, but it does not guarantee oral absorption, tissue targeting or clinical safety. Dipeptides can be transported intact, broken down into individual amino acids or converted into metabolites.

Tryptophan is also a precursor to serotonin and other metabolites, but Thymogen evidence cannot be reduced to ordinary tryptophan supplementation. The intact molecule and its stereochemistry are central to the proposed pharmacology.

How is Thymogen connected to Thymalin?

Thymalin is a calf-thymus polypeptide mixture. Researchers fractionated or analysed thymus-derived material and identified short sequences thought to reproduce selected biological effects. L-Glu-L-Trp became Thymogen, a chemically defined compound.

Moving from an extract to a two-residue molecule improves chemical clarity. It does not mean that Thymogen reproduces every effect attributed to Thymalin, or that Thymalin evidence proves Thymogen efficacy.

The two require separate manufacturing controls, exposure studies and clinical trials.

Is Thymogen the same as thymodepressin?

No. Thymogen uses L-amino acids and is described as immunostimulating in its original programme. Thymodepressin uses the corresponding D-amino-acid configuration and has been investigated for immunosuppressive activity.

Molecules with the same sequence order but mirror-image amino acids are stereoisomers. Biological receptors and enzymes can distinguish them, leading to different or opposite effects.

A mass measurement alone may not distinguish stereoisomers. Chiral identity therefore belongs in quality control.

How was Thymogen developed?

PeriodDevelopment
1970s to 1980sSoviet researchers developed the Thymalin extract and investigated active short sequences
1980s to 1990sSynthetic L-Glu-L-Trp was developed and studied as Thymogen in immune dysfunction
1990sRussian studies expanded into respiratory, surgical and stress-related settings
2000A randomised Phase II study reported an apparent signal for intranasal IM862 in AIDS-related Kaposi's sarcoma
2004A 202-person Phase III trial found IM862 ineffective for Kaposi's sarcoma
2004 to 2007Renal-cell and prostate-cancer studies did not establish clinical efficacy
2011 onwardRussian perioperative and mechanistic studies continued, while no FDA, MHRA or EMA approval followed

Phase II studies explore activity and dose in a patient group but are not designed to confirm benefit reliably. Phase III studies are larger confirmatory trials intended to establish whether a treatment improves prespecified outcomes compared with placebo or standard care.

How is Thymogen proposed to affect immunity?

The original research programme describes effects on T-cell differentiation, inflammatory signalling and cyclic nucleotides inside immune cells. T cells are white blood cells that coordinate immune responses and kill infected or abnormal cells.

Later laboratory work has explored gene expression and DNA interactions involving the EW sequence. A reported binding preference or gene change in cells does not establish improved resistance to infection.

The immune system requires balance rather than maximum activation. A useful immunomodulator would need to improve a defined clinical outcome without provoking autoimmunity, inflammation or interference with immune tolerance.

What human immune evidence exists?

Russian reviews cite Thymogen studies in chronic illness, respiratory infections and states of immune dysfunction. Reports often focus on lymphocyte counts, T-cell subtypes or infection frequency.

Much of this evidence is difficult to evaluate from English-language sources. Trial registration, prespecified outcomes, randomisation methods, masking and complete adverse-event tables are commonly unavailable.

Human exposure and immune-marker changes are therefore documented more convincingly than broad clinical benefit. A higher cell count is a surrogate marker, not proof that patients avoid serious infection or live longer.

What did the perioperative study report?

A Russian paper describes a double-blind, randomised, placebo-controlled study in older adults preparing for surgery for solid tumours in the abdominal or retroperitoneal space. Double-blind means participants and outcome assessors were intended not to know who received Thymogen or placebo.

The abstract reports correction of selected immune disturbances and clinical benefit around surgery. However, it does not provide enough accessible information about participant numbers by group, the complete outcome hierarchy, effect sizes, confidence intervals or adverse events.

That design is stronger than an uncontrolled case series, but the limited report prevents a dependable judgement about reduced infections, surgical complications or survival. It does not establish routine perioperative use.

Why was L-Glu-L-Trp studied in cancer?

Under the name IM862, L-Glu-L-Trp was developed as an inhibitor of angiogenesis, the formation of new blood vessels. Tumours often stimulate blood-vessel growth to obtain oxygen and nutrients.

Immune and endothelial experiments suggested a possible way to slow tumour growth. Endothelial cells line blood vessels. A mechanistic anti-angiogenic signal does not prove that a compound shrinks tumours or extends survival.

Cancer development provided more rigorous independent tests than much of the older immune literature. Those controlled results were negative.

What happened in the Phase II Kaposi's sarcoma study?

Kaposi's sarcoma is a cancer caused by human herpesvirus 8, particularly important in people with advanced human immunodeficiency virus, or HIV. A randomised Phase II study tested two intranasal IM862 schedules in 44 evaluable participants with AIDS-related Kaposi's sarcoma.

The study reported tumour responses and tolerability, creating interest in a larger trial. It did not include a placebo group, and effective antiretroviral therapy was changing the natural history of the disease at the same time.

Without placebo, improvement due to HIV control or natural variation could be attributed incorrectly to IM862. The later Phase III study directly tested that possibility.

What did the Phase III Kaposi's sarcoma trial find?

The Phase III trial enrolled 202 HIV-positive participants with Kaposi's sarcoma. Participants were randomly assigned under double-blind conditions to intranasal IM862 or placebo while receiving contemporary HIV care.

Tumour response occurred in 23% of the IM862 group and 21% of the placebo group, a difference that was not statistically significant. Median time to disease progression was 16 weeks with IM862 and 35 weeks with placebo. The investigators concluded that IM862 was ineffective and that earlier apparent activity was largely explained by highly active antiretroviral therapy.

The shorter progression time raises concern, though one trial does not prove that the molecule accelerates every cancer. It decisively prevents use of the Phase II result as evidence of anti-cancer efficacy.

What did the prostate-cancer trial find?

A randomised, double-blind, placebo-controlled study used a treatment-free interval after temporary androgen suppression to screen IM862 in men with rising prostate-specific antigen, or PSA, after local treatment. PSA is a blood protein used to monitor prostate cancer, although a PSA change is not itself a direct measure of symptoms or survival.

Among 71 evaluable participants, PSA progression at six months occurred in 41% with IM862 and 49% with placebo. The difference was not statistically significant. The study concluded that IM862 failed to demonstrate superiority over placebo in prolonging time to PSA progression.

Well tolerated does not mean effective. The result supplies human safety context within that study but no basis for treating prostate cancer.

What did the renal-cell carcinoma study show?

A Phase II study examined IM862 in people with metastatic renal-cell carcinoma, a kidney cancer that had spread. It was a small development study rather than a definitive placebo-controlled trial.

The programme did not establish a response or survival benefit sufficient for approval. Results from one tumour type also cannot be transferred to immune ageing or infection prevention.

Does Thymogen slow ageing or prevent cancer?

Animal work reported that L-Glu-L-Trp altered lifespan and spontaneous tumour incidence in rats. Rodent lifespan studies can generate hypotheses but are sensitive to strain, housing, infection, food intake and pathology classification.

The negative controlled human cancer trials argue strongly against describing the molecule as a demonstrated anti-cancer treatment. No confirmatory human trial shows slower ageing, fewer age-related diseases or longer life.

Does it protect against respiratory infections?

Russian literature describes Thymogen in respiratory illness and infection prevention, but accessible evidence does not establish a reproducible effect through large, well-reported randomised trials.

Immune-marker changes cannot substitute for clinically important outcomes such as laboratory-confirmed infection, hospital admission, complications or mortality. Evidence for a vaccine or thymosin alpha-1 should not be credited to Thymogen.

How is Thymagen synthesised and characterised?

L-Glu-L-Trp can be produced by solid-phase peptide synthesis using protected L-glutamic acid and L-tryptophan building blocks. One amino acid is attached to a resin support, the second is coupled, and protecting groups prevent unwanted reactions at side chains. The product is then released, deprotected and purified.

Glutamic acid has more than one carboxyl group, so manufacture must confirm which group forms the peptide bond. Tryptophan can oxidise, and both residues must retain the intended L configuration.

Quality testing can include intact mass, nuclear magnetic resonance or sequence confirmation, chromatographic related substances, chiral analysis, peptide content, water, counterions and residual solvents. A functional assay may be needed when pharmaceutical equivalence is claimed.

Sterile investigational material requires separate controls for sterility, bacterial endotoxin, particles, concentration, stability and container compatibility. A research certificate reporting high-performance liquid chromatography purity does not establish equivalence to Thymogen or IM862 used in trials.

What is known about pharmacokinetics?

Published development describes intranasal and other formulations, but there is no general pharmacokinetic profile that can be transferred to every material called Thymagen. Route and formulation change absorption and exposure.

As a dipeptide, L-Glu-L-Trp may be transported intact, degraded by peptidases or cleared rapidly. Adding lipid groups or converting the terminal acid to an amide creates an analogue, not ordinary Thymogen.

Study administration levels are research context only and do not establish personal use. No validated self-administration amount follows from the trials.

What is known about safety?

The cancer trials provide more systematic human exposure than most peptide-catalogue summaries acknowledge. IM862 was generally described as tolerable within those protocols, but it did not deliver the intended benefit.

Safety depends on formulation, route, duration, population and product quality. Negative efficacy does not prove long-term safety in healthy people or in those using an unverified research product.

Potential areas requiring study include immune imbalance, hypersensitivity, effects on blood-vessel biology, interactions with cancer or immune treatments and consequences of the wrong stereochemical form. There is no FDA, MHRA or EMA-approved label defining contraindications and interactions.

Is Thymogen approved?

Thymogen has a medicine history and regulatory status in Russia, but L-Glu-L-Trp is not approved by the FDA, MHRA or EMA for cancer, immune ageing, infection prevention or another indication.

Approval in one country applies to a specific manufacturer, formulation and use. It does not validate material sold internationally as Thymagen, and it does not override the negative controlled cancer trials.

How strong is the evidence overall?

QuestionBest available evidenceDefensible conclusion
Does L-Glu-L-Trp affect immune biology?Cell, animal and older human marker studiesBiological activity is plausible; broad clinical benefit is unconfirmed
Does it improve perioperative outcomes?One reported randomised study with limited accessible detailInsufficient evidence for routine use
Does it treat Kaposi's sarcoma?202-person randomised Phase III trialNo benefit over placebo; time to progression was shorter
Does it delay prostate-cancer progression?Randomised placebo-controlled studySuperiority was not demonstrated
Does it slow ageing or prevent cancer?Rat studies and indirect mechanismsNot established in humans
Is every Thymagen product equivalent to Thymogen or IM862?No universal product standardNo
Is it approved by FDA, MHRA or EMA?No approvalNo

The evidence is more substantial than a purely preclinical peptide, but its best-controlled trials do not support the largest therapeutic claims.

What claims are not established?

Thymagen has not been shown to rebuild the thymus, reverse immune ageing, prevent respiratory infections, increase lifespan or treat cancer. It is not an evidence-based substitute for vaccination, anti-infective treatment, cancer therapy or management of immune disease.

There is no validated self-administration protocol and no controlled evidence that combining it with Thymalin, Epitalon, thymosin alpha-1 or other bioregulators improves outcomes.

FREQUENTLY ASKED QUESTIONS

Frequently asked questions

Is Thymagen the same as Thymogen?

The name Thymagen usually refers to the same L-Glu-L-Trp sequence, but product equivalence requires confirmation of structure, stereochemistry and formulation.

What does EW mean?

E is the one-letter code for glutamic acid and W is the code for tryptophan.

Is Thymagen part of Thymalin?

The EW sequence was developed through analysis of Thymalin-related material. Synthetic Thymogen is a separate defined molecule, not the whole extract.

Is Thymagen the same as thymosin alpha-1?

No. Thymosin alpha-1 contains 28 amino acids and has a separate clinical record.

Is it the same as thymodepressin?

No. Thymodepressin uses the mirror-image D-amino-acid form and has different reported immune activity.

Does Thymagen strengthen immunity?

Immune-marker effects have been reported, but broad protection against infection has not been confirmed in modern trials.

Does it treat cancer?

No. Controlled Kaposi's sarcoma and prostate-cancer trials failed to show clinical superiority over placebo.

Has Thymagen been tested in humans?

Yes. L-Glu-L-Trp has human exposure under the names Thymogen and IM862, including randomised trials.

Is Thymagen known to be safe?

IM862 was generally tolerated in cancer studies, but that does not establish long-term safety for every population, route or product.

Is Thymagen approved?

Thymogen has a Russian medicine history, but the compound is not approved by the FDA, MHRA or EMA.

Research reviewed through October 2026.